1
Return

Precision neoadjuvant treatment with AI-assisted subtyping in HR+/HER2−breast cancer: A randomized, phase 2 trial FASCINATE-N

delete2026-08-06
delete0
delete
OA
AI
J
Jun-Jie Li *
L
Lin-Xiaoxi Ma
P
Peng Ji
L
Li Chen
J
Jiong Wu
G
Guang-Yu Liu
Y
Yi-Feng Hou
G
Gen-Hong Di
Z
Zhen Hu
Y
Yi-Zhou Jiang
L
Lei Fan
Z
Zhong-Hua Wang
K
Ke-Da Yu *
Z
Zhi-Ming Shao *
DOI：10.1016/j.xcrm.2026.102977delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
• SNF subtyping guides precision neoadjuvant therapy for HR+/HER2− breast cancer • Endocrine-CDK4/6i yields chemotherapy-like efficacy with superior tolerance • Targeted-based precision therapy improves pCR with manageable toxicity • Subtype-directed therapy optimizes outcome for early HR+/HER2− breast cancer
Keywords:
breast cancer
neoadjuvant
HR+/HER2−
precision treatments
pathological complete response

Journal

Cell Reports Medicine cover
Cell Reports Medicine
IF:
10.6
Papers:
2.2K
Citations:
8.9K

Organization

K
Key Laboratory of Breast Cancer in Shanghai
Scholars:
47
Papers: 4
Citations: 0
Cited Papers

Cited Papers

Citing Papers

Citing Papers